In a multicenter, randomized, double-blind study the authors compared the efficacy of
modafinil 400 mg once daily, 400 mg given in a split dose, or 200 mg once daily for …

Modafinil is used internationally to treat residual sleepiness despite continuous positive
airway pressure in obstructive sleep apnoea (res-OSA). In 2011, the European Medicines …

Objective: This study assessed the efficacy and safety of armodafinil, the longer half-life
enantiomer of modafinil, for the treatment of excessive sleepiness in patients with …

Idiopathic hypersomnia is a central hypersomnolence disorder of unknown origin
characterized by excessive daytime sleepiness despite normal or long sleep time, and …

Objective: The purpose of this paper is to summarize current knowledge about treatment of
narcolepsy and other hypersomnias of central origin. Methods: The task force performed a …

Background Excessive sleepiness (ES) is a common symptom of OSA, which often persists
despite primary OSA therapy. This phase III randomized withdrawal trial evaluated …

Summary In 2010 the European Medicines Agency withdrew the indication of modafinil for
the treatment of obstructive sleep apnea, shift work sleep disorder and for idiopathic …

Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake
inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the …

Abstract Study Objectives: Nasal continuous positive airway pressure (nCPAP) usually
reduces sleepiness in patients with obstructive sleep apnea/hypopnea syndrome. However …

Background Modafinil is a novel wake-promoting agent approved by the FDA ameliorating
excessive daytime sleepiness (EDS) in three disorders: narcolepsy, shift work sleep disorder …